Role of Antibodies Against Glutamate Receptors and Double Stranded DNA in Epilepsy Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00317668

Enrollment

250

Registered

2006-04-25

Start date

2006-11-30

Completion date

Unknown

Last updated

2007-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy

Brief summary

The investigators will check the serum of epilepsy patients for antibodies against glutamate receptors and double stranded DNA. They will characterise the patients (by the kind of epilepsy, autoimmune disease comorbidity, and cognitive profile).

Interventions

None listed

Study design

Observational model

DEFINED_POPULATION

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* 120 epilepsy patients from the epilepsy clinic and Emergency Room (ER) * Controls: 100 patients with other neurological diseases and no epilepsy; and 30 healthy volunteers.

Countries

Israel

Contacts

Primary ContactDana Ekstein, MD

dekstein@md.huji.ac.il

Outcome results